The next microbiome trend to know—and what the evidence really shows
Industry Buzz
Postbiotics are particularly supportive for individuals with gut barrier dysfunction, inflammation, poor immune regulation, or if you have IBS or SIBO, and can’t tolerate live probiotics.
—Jessica O'Dwyer. nutritionist
In recent months, hype about "postbiotics" has likely migrated from wellness blogs and consumer supplements into discussions in the exam room.
Postbiotics are increasingly marketed and discussed as a "next-generation biotic therapy"—but what does the current science actually say about their therapeutic potential?
A refresher on postbiotics
Unlike prebiotics (fibers that feed the microbiota) and probiotics (live microbes intended to confer benefit), postbiotics are nonviable microbial products—metabolites, structural components, and other bioactive compounds generated by microbial fermentation or produced during bacterial metabolism.[]
Key biochemical classes include short-chain fatty acids (SCFAs) such as butyrate and propionate, bacterial lysates, exopolysaccharides, and discrete microbial peptides or enzymes. These components are well-positioned, mechanistically, to modulate the host immune system, enhance epithelial barrier function, and improve local metabolic signaling. []
Related: Benefits and drawbacks of probiotics: How much is too much?How postbiotics work to support the gut
Mechanistic data suggest several plausible pathways through which postbiotics may support gut homeostasis:
Barrier function: SCFAs, particularly butyrate, are primary energy substrates for colonocytes and reinforce tight junction protein expression, potentially counteracting “leaky gut” phenotypes seen in inflammatory disorders.[]
Immune modulation: Certain postbiotic components interact with pattern recognition receptors (eg, TLRs) on immune cells, shaping cytokine profiles and mucosal immune responses. []
Anti-inflammatory effects: In vitro and animal studies show that postbiotic fractions can attenuate pro-inflammatory cytokines and downstream tissue inflammation without live organisms.[]
Metabolic signaling: SCFAs also influence enteroendocrine signaling through G-protein-coupled receptors, with downstream effects on GLP-1 and PYY secretion, potentially relevant in gut-metabolic crosstalk.[]
Compared with probiotics, the clinical portfolio for postbiotics remains nascent but growing. Consider the following:
Inflammation and barrier disorders: Early systematic reviews report anti-inflammatory effects and improved epithelial integrity in preclinical and small clinical models, though heterogeneity in formulations limits firm conclusions. []
Metabolic health: A 2025 meta-analysis of 25 RCTs found that postbiotic supplementation significantly lowered serum insulin, triglycerides, CRP, and waist circumference—suggesting potential metabolic benefits, but with variability in formulation and endpoints.[]
Gut-specific outcomes: Data on conditions most relevant to gastroenterology—for example, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), small intestinal bacterial overgrowth, and antibiotic-associated diarrhea—remain limited, often extrapolated from SCFA physiology or pilot studies rather than large, disease-specific trials.[]
Practical considerations for clinicians
For practicing gastroenterologists, the current data landscape suggests cautious optimism. "Postbiotics are particularly supportive for individuals with gut barrier dysfunction, inflammation, poor immune regulation, or if you have IBS or SIBO, and can’t tolerate live probiotics," nutritionist Jessica O'Dwyer told The Independent.[]
However, there are some important caveats:
Standardization challenges: Postbiotic products are heterogeneous—varying in metabolite profiles, manufacturing processes (eg, heat-inactivated vs enzymatic extracts), and doses. This complicates comparisons and clinical recommendations. []
Target populations: The safety data of postbiotics are "limited for severely immunocompromised individuals, critically ill patients, or those with unstable autoimmune conditions." []
Safety: Generally favorable, yet mild GI symptoms can occur during initiation, and robust safety data in high-risk populations are lacking. []"Postbiotics safety data is limited for severely immunocompromised individuals, critically ill patients, or those with unstable autoimmune conditions," nutritional therapist Ruchi Bhuwania Lohia told The Independent.[]
Your takeaway
Postbiotics represent a mechanistically compelling category of microbial therapeutics with early supportive evidence for roles in barrier reinforcement, immune modulation, and metabolic regulation.
For specialists managing IBD, IBS, and other complex gut disorders, postbiotics may soon augment existing biotic strategies—but more targeted RCTs, standardized formulations, and disease-specific endpoints are required before broad integration into practice guidelines.